AR095708A1 - Indazoles sustituidos con diaminoheteroarilo - Google Patents
Indazoles sustituidos con diaminoheteroariloInfo
- Publication number
- AR095708A1 AR095708A1 ARP140101321A ARP140101321A AR095708A1 AR 095708 A1 AR095708 A1 AR 095708A1 AR P140101321 A ARP140101321 A AR P140101321A AR P140101321 A ARP140101321 A AR P140101321A AR 095708 A1 AR095708 A1 AR 095708A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- optionally substituted
- hydrogen
- haloalkyl
- optionally
- Prior art date
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 12
- 229910052739 hydrogen Inorganic materials 0.000 abstract 11
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 10
- 239000001257 hydrogen Substances 0.000 abstract 10
- 150000002431 hydrogen Chemical group 0.000 abstract 6
- 229910052757 nitrogen Inorganic materials 0.000 abstract 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical group 0.000 abstract 4
- 125000005842 heteroatom Chemical group 0.000 abstract 4
- 125000004043 oxo group Chemical group O=* 0.000 abstract 4
- 229910052760 oxygen Inorganic materials 0.000 abstract 4
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract 2
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 abstract 2
- 150000001204 N-oxides Chemical class 0.000 abstract 2
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- -1 cyano, hydroxy Chemical group 0.000 abstract 2
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 abstract 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 abstract 1
- 125000003341 7 membered heterocyclic group Chemical group 0.000 abstract 1
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 abstract 1
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicación 1: Un compuesto de fórmula (1) en donde X es CR⁶, N; Y es CH, N; R¹ es hidrógeno, halógeno, alquilo C₁₋₃; R² / R³ son en forma independiente entre sí hidrógeno, halógeno, ciano, hidroxi, haloalquilo C₁₋₆, haloalcoxi C₁₋₆, alcoxi C₁₋₆; R⁴ es en forma independiente hidrógeno, hidroxi, halógeno, ciano, alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, haloalquilo C₁₋₆, hidroxialquilo C₁₋₆, alcoxi C₁₋₆, -O-(alquilen C₂₋₄)-O-C(O)-(alquilo C₁₋₄), haloalcoxi C₁₋₆, -C(O)OR⁹, -C(O)-(alquilo C₁₋₆), -C(O)NR¹⁰R¹¹, cicloalquilo C₃₋₇, -S(O)₂NH-(cicloalquilo C₃₋₆), -S(O)₂NR¹⁰R¹¹, heteroarilo que está opcionalmente sustituido en forma independiente una o más veces con ciano, alquilo C₁₋₄, haloalquilo C₁₋₄, haloalcoxi C₁₋₄, donde dos de R², R³ (R⁴)ₙ, cuando están en posición orto entre sí, pueden formar junto con los dos átomos de carbono a los cuales están unidos, un anillo heterocíclico de 5, 6, ó 7 miembros que contiene 1 ó 2 heteroátomos seleccionados entre O ó N, y que contiene opcionalmente un doble enlace adicional y/o está opcionalmente sustituido con un grupo oxo (=O) y/o un grupo alquilo C₁₋₄; n es 0, 1, 2 ó 3; R⁵ es (a) hidrógeno; (b) -C(O)-(alquilo C₁₋₆); (c) -C(O)-(alquilen C₁₋₆)-O-(alquilo C₁₋₆); (d) -C(O)NH-(alquilo C₁₋₆); (e) un resto de fórmula (2), donde el * es el punto de unión; R⁶ es (a) hidrógeno; (b) hidroxi; (c) ciano; (d) alcoxi C₁₋₆ opcionalmente sustituido en forma independiente una o más veces con (d1) OH, (d2) -O-(alquilo C₁₋₆), (d3) -C(O)NR¹⁰R¹¹, (d4) -NR¹²R¹³, (d5) -S-(alquilo C₁₋₆), (d6) -S(O)-(alquilo C₁₋₆), (d7) -S(O)₂-(alquilo C₁₋₆), (d8) -S(O)₂NR¹⁰R¹¹, (d9) heterociclilo, que está opcionalmente sustituido con oxo (=O), (d10) heteroarilo, que está opcionalmente sustituido en forma independiente una o más veces con ciano, alquilo C₁₋₄, haloalquilo C₁₋₄, haloalcoxi C₁₋₄, C₍O₎NR¹⁰R¹¹, (alquilen C₁₋₄)-O-(alquilo C₁₋₄), (e) -O-heteroarilo opcionalmente sustituido con CN, (f) el resto de fórmula (3), donde el * es el punto de unión, (g) -O-(alquilen C₂₋₆)-O-(alquilo C₁₋₆) que está opcionalmente sustituido con hidroxi, (h) -NR¹²R¹³, (i) -NHS(O)₂-(alquilo C₁₋₆), (j) -NHS(O)₂-(haloalquilo C₁₋₆), u opcionalmente, R⁵ y R⁶ forman un anillo de 6 miembros con el átomo de nitrógeno al cual R⁵ esta unido y junto con los átomos de carbono del anillo pirimidina al cual R⁵-NH y R⁶ están unidos que puede contener un heteroátomo adicional seleccionado del grupo que consiste en O, S, N, y que está opcionalmente sustituido con un grupo oxo (=O); R⁷ es (a) hidrógeno, (b) alquilo C₁₋₄, que está opcionalmente sustituido con heteroarilo, (c) haloalquilo C₁₋₄, (d) hidroxialquilo C₂₋₄, (e) un resto de fórmula (2), donde el * es el punto de unión; R⁸ es en forma independiente hidrógeno, halógeno, hidroxi, alquilo C₁₋₄, hidroxialquilo C₁₋₄, haloalquilo C₁₋₄, haloalcoxi C₁₋₄, C₍O₎OR⁹, C(O)NR¹⁰R¹¹; m es 0, 1, 2, 3 ó 4; R⁹ es (a) hidrógeno, (b) alquilo C₁₋₄ que está opcionalmente sustituido con hidroxi; R¹⁰, R¹¹ son en forma independiente entre sí hidrógeno, alquilo C₁₋₄, hidroxialquilo C₂₋₄, o junto con el átomo de nitrógeno al cual están unidos forman un anillo heterocíclico de 4 - 6 miembros que contiene opcionalmente un heteroátomo adicional seleccionado del grupo que consiste en O, S o N, y que está opcionalmente sustituido con 1 - 2 átomos de flúor o C(O)OR⁹; R¹², R¹³ son en forma independiente entre sí hidrógeno, alquilo C₁₋₄, hidroxialquilo C₂₋₄, -C(O)-(alquilo C₁₋₆), -C(O)-(alquilen C₁₋₆)-O-(alquilo C₁₋₆), -C(O)H, C(O)OR⁹, o junto con el átomo de nitrógeno al cual están unidos forman un anillo heterocíclico de 4 - 6 miembros que contiene opcionalmente un heteroátomo adicional seleccionado del grupo que consiste en O, S o N, y que está opcionalmente sustituido con un grupo oxo (=O); o un N-óxido, una sal, un tautómero o un estereoisómero de dicho compuesto, o una sal de dicho N-óxido, tautómero o estereoisómero.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13160350 | 2013-03-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR095708A1 true AR095708A1 (es) | 2015-11-04 |
Family
ID=47900948
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140101321A AR095708A1 (es) | 2013-03-21 | 2014-03-21 | Indazoles sustituidos con diaminoheteroarilo |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20160052912A1 (es) |
| EP (1) | EP2976334A1 (es) |
| JP (1) | JP2016514717A (es) |
| CN (1) | CN105051030A (es) |
| AR (1) | AR095708A1 (es) |
| CA (1) | CA2907730A1 (es) |
| HK (1) | HK1217324A1 (es) |
| TW (1) | TW201514167A (es) |
| UY (1) | UY35499A (es) |
| WO (1) | WO2014147144A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA111754C2 (uk) | 2011-10-06 | 2016-06-10 | Байєр Фарма Акцієнгезелльшафт | Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань |
| WO2013092512A1 (en) | 2011-12-21 | 2013-06-27 | Bayer Intellectual Property Gmbh | Substituted benzylpyrazoles |
| WO2014147204A1 (en) * | 2013-03-21 | 2014-09-25 | Bayer Pharma Aktiengesellschaft | Heteroaryl substituted indazoles |
| CN105209455A (zh) * | 2013-03-21 | 2015-12-30 | 拜耳制药股份公司 | 3-杂芳基取代的吲唑 |
| ES2652305T3 (es) | 2013-06-21 | 2018-02-01 | Bayer Pharma Aktiengesellschaft | Pirazoles heteroaril sustituidos |
| JP2016525076A (ja) | 2013-06-21 | 2016-08-22 | バイエル ファーマ アクチエンゲゼルシャフト | 置換されたベンジルピラゾール類 |
| CN105764893A (zh) | 2013-10-30 | 2016-07-13 | 拜耳制药股份公司 | 杂芳基取代的吡唑 |
| CN106715415B (zh) | 2014-06-17 | 2019-06-14 | 拜耳制药股份公司 | 3-氨基-1,5,6,7-四氢-4h-吲哚-4-酮 |
| CU20170029A7 (es) | 2014-09-19 | 2017-08-08 | Bayer Pharma AG | Indazoles sustituidos con bencilo en calidad de inhibidores de bub1, útiles para el tratamiento o profilaxis de una enfermedad hiperproliferativa y/o un trastorno que responde a la inducción de la muerte celular, un procedimiento para la preparación de estos compuestos, y compuestos intermediarios |
| WO2018122168A1 (en) | 2016-12-29 | 2018-07-05 | Bayer Pharma Aktiengesellschaft | Combinations of bub1 kinase and parp inhibitors |
| WO2018158175A1 (en) | 2017-02-28 | 2018-09-07 | Bayer Pharma Aktiengesellschaft | Combination of bub1 inhibitors |
| KR102615821B1 (ko) | 2017-04-11 | 2023-12-21 | 선샤인 레이크 파르마 컴퍼니 리미티드 | 불소-치환된 인다졸 화합물 및 이의 용도 |
| WO2018206547A1 (en) | 2017-05-12 | 2018-11-15 | Bayer Pharma Aktiengesellschaft | Combination of bub1 and atr inhibitors |
| WO2018215282A1 (en) | 2017-05-26 | 2018-11-29 | Bayer Pharma Aktiengesellschaft | Combination of bub1 and pi3k inhibitors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2331889A1 (en) * | 1998-06-16 | 1999-12-23 | Sugen, Inc. | Nek-related and bub1-related protein kinases |
| US7378532B2 (en) * | 2004-03-26 | 2008-05-27 | Yung Shin Pharmaceutical Ind. Co., Ltd. | Fused pyrazolyl compound |
| JP2010111624A (ja) * | 2008-11-06 | 2010-05-20 | Shionogi & Co Ltd | Ｔｔｋ阻害作用を有するインダゾール誘導体 |
| JP5766177B2 (ja) * | 2009-03-27 | 2015-08-19 | ベトディーシー，インコーポレイテッド | ピリミジニル及び１，３，５−トリアジニルベンゾイミダゾールスルホンアミド及びガンの療法におけるその使用 |
| UA111754C2 (uk) * | 2011-10-06 | 2016-06-10 | Байєр Фарма Акцієнгезелльшафт | Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань |
| WO2013092512A1 (en) * | 2011-12-21 | 2013-06-27 | Bayer Intellectual Property Gmbh | Substituted benzylpyrazoles |
| EP2847180B1 (en) * | 2012-05-11 | 2017-01-04 | Bayer Pharma Aktiengesellschaft | Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer |
| WO2014147204A1 (en) * | 2013-03-21 | 2014-09-25 | Bayer Pharma Aktiengesellschaft | Heteroaryl substituted indazoles |
| CN105209455A (zh) * | 2013-03-21 | 2015-12-30 | 拜耳制药股份公司 | 3-杂芳基取代的吲唑 |
-
2014
- 2014-03-19 US US14/778,604 patent/US20160052912A1/en not_active Abandoned
- 2014-03-19 CN CN201480017090.3A patent/CN105051030A/zh active Pending
- 2014-03-19 WO PCT/EP2014/055540 patent/WO2014147144A1/en active Application Filing
- 2014-03-19 EP EP14710931.8A patent/EP2976334A1/en not_active Withdrawn
- 2014-03-19 CA CA2907730A patent/CA2907730A1/en not_active Abandoned
- 2014-03-19 JP JP2016503655A patent/JP2016514717A/ja active Pending
- 2014-03-21 TW TW103110771A patent/TW201514167A/zh unknown
- 2014-03-21 AR ARP140101321A patent/AR095708A1/es unknown
- 2014-03-24 UY UY0001035499A patent/UY35499A/es not_active Application Discontinuation
-
2016
- 2016-05-09 HK HK16105232.9A patent/HK1217324A1/zh unknown
-
2017
- 2017-03-28 US US15/471,885 patent/US20170283396A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2976334A1 (en) | 2016-01-27 |
| JP2016514717A (ja) | 2016-05-23 |
| CN105051030A (zh) | 2015-11-11 |
| WO2014147144A1 (en) | 2014-09-25 |
| US20160052912A1 (en) | 2016-02-25 |
| UY35499A (es) | 2014-10-31 |
| TW201514167A (zh) | 2015-04-16 |
| HK1217324A1 (zh) | 2017-01-06 |
| US20170283396A1 (en) | 2017-10-05 |
| CA2907730A1 (en) | 2014-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR095708A1 (es) | Indazoles sustituidos con diaminoheteroarilo | |
| AR095706A1 (es) | Indazoles sustituidos con heteroarilo | |
| AR088449A1 (es) | Benzilindazoles sustituidos | |
| AR094299A1 (es) | Derivados de ftalazin-1(2h)-ona sustituidos | |
| PE20171240A1 (es) | Derivados de 4h-pirrol[3,2-c]piridin-4-ona | |
| PE20161405A1 (es) | Analogos de cortistatina y sintesis y usos de los mismos | |
| ES2567311T3 (es) | 6-(3-Aza-biciclo[3.1.0]hex-3-il)-2-fenil-pirimidinas como antagonistas del receptor de ADP | |
| AR099498A1 (es) | Compuestos de triazina y su uso farmacéutico | |
| AR098171A1 (es) | Piridinilimidazolonas como herbicidas | |
| AR088828A1 (es) | DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3 | |
| ES2603931T3 (es) | Compuestos de triazolo | |
| ES2626801T3 (es) | Compuestos de triazolopiridina como inhibidores de pde10a | |
| AR102544A1 (es) | Compuestos derivados de dihidrohidantoína como herbicidas | |
| AR100940A1 (es) | Derivados de 1,2,4-triazoles plaguicidas, y sus intermediarios, composiciones y sus procesos relacionados | |
| AR090572A1 (es) | Derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos | |
| AR107321A1 (es) | Compuestos antiproliferativos, y sus composiciones farmacéuticas y usos | |
| AR103742A1 (es) | Derivados de trifluorometilpropanamida | |
| AR069814A1 (es) | Derivados de 4 amino-pirimidina, proceso de preparacion y composiciones farmaceuticas que los contienen | |
| AR096613A1 (es) | Moduladores de la acetil-coa carboxilasa | |
| AR109296A1 (es) | Derivados de oxadiazolopiridina para el uso como inhibidores de ghrelin o-aciltransferasa (goat) | |
| AR095136A1 (es) | Derivados de pirazol microbiocidas | |
| AR095267A1 (es) | Compuestos inhibidores de la fosfodiesterasa del tipo 10a | |
| AR102258A1 (es) | Compuestos de quinolina y quinazolina | |
| AR113811A1 (es) | Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos | |
| ES2568909T3 (es) | Novedosos compuestos antagonistas del receptor de la neuroquinina 1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |